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Abstract
Mesangial cells are thought to be important mediators of
glomerular inflammation and fibrosis. Studies have
established a direct role for nitric oxide (NO) in the regu-
lation of gene expression in mesangial cells. Represen-
tational difference analysis was used to investigate
changes in gene expression elicited by the treatment of
S-nitroso-L-glutathione in rat mesangial cells. Seven
upregulated and 11 downregulated genes were identi-
fied. Four out of 11 downregulated genes (connective tis-
sue growth factor, thrombospondin-1, collagen type I a1
and collagen type I a2) are known to be linked to inflam-
mation and fibrosis. Results were verified across species
in mesangial cells treated with a series of NO donors
using Northern blot analysis, quantitative real-time PCR
and protein analysis methods. Induction of endogenous
NO production by cytokine stimulation also triggered reg-
ulation of the genes. One example gene, connective tis-
sue growth factor, was studied at the promoter level.
Promoter-reporter gene studies in mesangial cells dem-
onstrated that NO acts at the transcriptional level to sup-
press gene expression. Our results reveal a complex role
of NO in regulating gene expression in mesangial cells
and suggest an antifibrotic potential for NO.
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Introduction
Nitric oxide (NO) is a major signal transduction molecule
in vertebrates. NO is produced in response to stress
(Ohno et al., 1993) and can lead to tissue injury because
of its radical chemistry, or be cytoprotective by destroy-
ing pathogenic microorganisms (Guzik et al., 2003). NO
causes the relaxation of vascular smooth muscles (Blat-
ter and Wier, 1994) and has antiproliferative effects on
mesangial cells (Rupprecht et al., 2000). Interactions of
mesangial cells (MCs) with components of the extracel-
lular matrix (ECM) influence MC attachment, contraction,
migration, survival and proliferation. MCs are thought to
be important mediators of glomerular inflammation and
fibrosis via their proliferative and secretory potential.
ECM deposition leads to glomerular inflammation and
fibrosis. Recent studies have identified a direct role for
NO in the regulation of gene expression in different cell
types, including MCs. However, the extent and level at
which NO regulates the expression of ECM genes in MCs
have not been systematically evaluated. NO has been
shown to activate diverse signaling pathways that affect
gene expression in mammalian cells (Hemish et al.,
2003). NO elicits changes in gene expression in rat MCs
and regulates the transcription of genes such as MIP-2,
MMP-9, SPARC, biglycan, IAP, HO-1 and Cu/Zn-SOD
(Bogdan, 2001; Pfeilschifter, 2002).
Glomerulonephritis progresses through the accumula-
tion of ECM and results in loss of the glomerular archi-
tecture and scarring (Habib, 1975; Rosenberg, 1986;
Oguma, 1988; Stengel, 2003). The pathogenesis of glo-
merulonephritis is incompletely understood, but the elic-
iting factor is thought to be an immunological injury to
resident cells in the glomeruli, e.g., MCs or podocytes.
In several animal models of chronic renal disease and
glomerular inflammation, an increase in NO synthesis on
administration of L-arginine has been shown to decrease
the degree of glomerulosclerosis, reduce matrix score
and attenuate focal glomerulosclerosis (reviewed by
Groves and Wang, 2000).
Endogenously synthesized NO can prevent endotoxin-
induced glomerular thrombosis (Shultz and Raij, 1992).
NO generated by the activation of iNOS has also been
shown to have a protective role against tubulointerstitial
injury and cytokine production in adriamycin nephropathy
(Rangan et al., 2001). Inhibition of iNOS in a rat model of
autoimmune interstitial nephritis showed host-protective
effects of endogenously generated NO in an organ-
specific manner (Gabbai et al., 1997).
To determine the extent to which NO regulates gene
expression in MCs, we used a PCR-based representa-
tional differential analysis (RDA) (Pastorian et al., 2000;
Hubank et al., 2004) technique in S-nitrosoglutathione
(GSNO)-treated rat MCs. To determine the level at which
these genes are regulated, we carried out mRNA half-life
and promoter experiments with one of the candidate
ECM genes, connective tissue growth factor (CTGF), in
rat and human MCs.
Results
Identification of genes differentially regulated by NO
To identify genes differentially expressed by NO, MCs
were treated with 500 mM GSNO for 4 h. PolyAq RNA
was isolated from control and GSNO-treated cells and
reverse-transcribed into cDNA. The cDNA was subtract-
ed by representational difference analysis (RDA) and 51
clones were isolated: 23 clones from subtraction pool A
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Table 1 List of differentially expressed genes in GSNO-treated rat
mesangial cells.
Pool ‘A’ or upregulated genes GenBank accession no.
Pyruvate kinase, muscle (Pkm) NM_053297
Hemochromatosis (Hfe) NM_053301
ATPase synthase subunit 6 AF504920
Tyrosine 3-monooxygenase (Ywahab) NM_019377
Integrin b 1 (Itgb1) NM_017022
Aldose reductase (Akr1b10) NM_001013084
Triosephosphate isomerase (Tpi1) NM_022922
Pool ‘B’ or downregulated genes
Poly(A) binding protein 1 (Pabpc1) NM_134353
Thrombospondin-1 (TSP-1) AF309630
Connective tissue growth factor (CTGF) NM_022266
Procollagen type 1 a1 (COL1A1) Z78279
Procollagen type 1 a2 (COL1A2) NM_0253356
Mitochondrial cytochrome B5 (Cyb5) NM_022245
G-rich sequence factor-1 (GRSF-1) XM_223327
Ornithine aminotransferase (Oat) NM_22521
Dimethylaminohydrolase 1 (Ddah1) NM_022297
mRNA for astrocytic phosphoprotein (PEA-15) AJ243949
Translation initiation factor 5 (Eif5) NM_020075
Rat MCs were incubated for 4 h in the presence or absence of 500 mM
S-nitroso-glutathione. The subtraction library was generated using cDNA
representational difference analysis consisting of upregulated pool A or
downregulated pool B genes. PCR products were cloned and sequenced
as described in the materials and methods section. Sequence analysis was
performed and compared to public databases using BLAST.
were identified as sequences representing upregulated
genes, and 28 clones from subtraction pool B were iden-
tified as sequences representing downregulated genes.
The cDNA inserts varied in size from 130 bp to 1.5 kb.
To test the differential expression of these cDNAs, two
identical dot blots (data not shown) were prepared and
hybridized with radiolabeled cDNA from pools A and B
(summarized in Table 1). A total of 45 clones showed
regulation in the dot blots. All 45 clones were sequenced
and the sequence data were aligned against the Gen-
Bank nucleotide (rat genome) database at the National
Center for Biotechnology Information (NIH, Bethesda,
MD, USA) using Blastn to search for sequence matches.
Seven gene sequences identified from pool A showed
upregulation in dot blots and had 98–100% homology to
different genes of diverse physiological relevance (Table
1). Eleven gene sequences from pool B (downregulated
genes) showed 98–100% homology to six well-charac-
terized matrix-associated genes and seven genes with
diverse biological significance (Table 1). Several
sequences from both pools were homologous to cloning
vector and ribosomal RNA gene sequences (data not
listed).
Exogenous NO donors downregulate mRNA
expression of ECM-linked genes in MCs
To validate the RDA findings predicting downregulation
of CTGF and TSP-1, we analyzed total RNA extracted
from spermine NONOate-stimulated human MCs (treated
with 5 ng/ml TGF-b1 and 30 mM glucose for 24 h prior
to NO stimulation to create a pro-fibrotic environment for
cells) by Northern blot analysis using gene-specific cDNA
probes. Time- and dose-dependent downregulation of
CTGF and TSP-1 mRNA (Figure 1A) was observed after
treatment with 500 mM spermine NONOate. Comparable
time-dependent downregulation of CTGF and TSP-1 was
observed when rat MCs were treated with 100–500 mM
spermine NONOate, NOC-18 or SNAP (data not shown).
COL1A2 mRNA in rat MCs was also time-dependently
downregulated by 500 mM spermine NONOate (Figure
1B), NOC-18 and SNAP (data not shown). We hypothe-
sized that NO might affect the expression of additional
matrix-associated genes. We therefore used quantitative
RT-PCR to determine the changes in mRNA expression
levels of COL1A1, COL1A2, CTGF and biglycan in human
MCs. We observed dose- and time-dependent downre-
gulation of gene expression of COL1A1, COL1A2, CTGF
and biglycan (Figure 1C i–iv) in response to spermine
NONOate stimulation.
Exogenous NO donors downregulate TSP-1 and
CTGF protein expression in MCs
Two example genes, TSP-1 and CTGF, were selected to
verify the effects of exogenous NO donors on protein
expression. Quiescent human MCs were treated for 24 h
with 5 ng/ml TGF-b1 and 30 mM glucose. Increasing
doses of spermine NONOate, SNAP and NOC-18 were
used to stimulate the cultured cells for an additional 12
or 24 h in the same medium. After 24 h of incubation,
conditioned media were harvested and TSP-1 protein
concentrations were determined by ELISA. A significant
(p-0.001) dose- and time-dependent decrease in TSP-1
protein content was observed for cells treated with sper-
mine NONOate, SNAP or NOC-18 at all time points and
concentrations. The only exception was observed for
100, 250 and 500 mM spermine NONOate at 12 h (Figure
2A–C). To investigate CTGF protein expression, equal
amounts of protein in conditioned media were subjected
to SDS-PAGE. CTGF protein was then detected using a
CTGF anti-human monoclonal antibody (FG-3019).
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Figure 1 Exogenous NO donors downregulate mRNA expression of ECM genes in human mesangial cells.
Quiescent human (A) or rat (B) mesangial cells were incubated with medium containing 30 mM glucose and 5 ng/ml TGF-b1 for 24 h
before stimulation with or without spermine NONOate at the concentrations and time points indicated. Total RNA (15mg) was isolated
and the expression levels of CTGF, TSP-1, COL1A2 and 18S rRNA were analyzed by Northern blotting (C). cDNA synthesized from
2 mg of total RNA from quiescent human mesangial cells grown in serum-free medium containing 30 mM glucose and 5 ng/ml TGF-
b1 for 24 h was subjected to real-time quantitative PCR using human RT-PCR fluorescent probes for CTGF, COL1A1, COL1A2,
biglycan (BGN), GAPDH and/or ribosomal RNA as described in the materials and methods section.
Strong CTGF protein expression was detected in the
control sample, which was reduced in intensity in NO-
treated samples (Figure 2D). Strong inhibition of CTGF
protein expression was demonstrated in samples treated
with 500 mM spermine NONOate and NOC-18.
INFg and BH4 stimulation of MCs leads to the
production of endogenous NO, which is reversed by
selective iNOS inhibitors
To investigate whether a combination of interferon g
(INFg) and tetrahydro-L-biopterin (BH4, a NOS co-factor)
can stimulate the release of NO and whether this phe-
nomenon is reversible by selective iNOS inhibitors in
MCs, rat and human quiescent MCs grown for 24 h were
treated in medium containing 5 ng/ml TGF-b1 and 30 mM
glucose with 200 U/ml INFg and 10 mM BH4, or INFg
alone for 0–24 h in the presence or absence of the iNOS
inhibitors 1400W, L-NIL and L-NMMA. Media were har-
vested at different time points and assayed for the pres-
ence or absence of nitrites by Griess assay. Nitrite
concentrations in media from INFg- and BH4-stimulated
cells were significantly higher (7 mM"SD; p-0.001) than
in media from untreated cells (2 mM "SD; p-0.001) in
multiple experiments. There was a significant decrease
(p-0.01 and 0.001) in nitrite accumulation in media from
cells treated with either L-NIL or 1400W (Figure 3A).
Because of its potent effects, 1400W was chosen as the
candidate inhibitor of iNOS enzyme activity for subse-
quent experiments.
Activation of iNOS by INFg and BH4 leads to
endogenously generated NO, which effectively
downregulates CTGF, TSP-1, COL1A1, COL1A2 and
biglycan mRNA in MCs
To demonstrate that INFg and BH4 stimulation of MCs
leads to the endogenous release of NO by enzymatic
activation of iNOS, and that this is in turn responsible for
the downregulation of select matricellular genes, the
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Figure 2 Exogenous NO donors downregulate TSP-1 and CTGF protein expression in human mesangial cells.
(A) Quiescent human mesangial cells were incubated with medium containing 30 mM glucose and 5 ng/ml TGF-b1 for 24 h before
stimulation with or without 100, 250 and 500 mM of (A) spermine NO, (B) NOC-18 and (C) SNAP for 12 and 24 h. Conditioned media
were collected after 12 and 24 h and secreted levels of TSP-1 were measured by ELISA as described in materials and methods.
Data represent mean"SD of eight cultures for each condition. TSP-1 levels were significantly lower (***p-0.001) compared to untreat-
ed controls at all concentrations of spermine NONOate at 24 h, NOC-18 at 12 and 24 h, and SNAP at 12 and 24 h. (D) Quiescent
human mesangial cells grown in medium containing 30 mM glucose and 5 ng/ml TGF-b1 for 24 h were treated or not with the
concentrations of spermine NONOate or NOC-18 indicated for 24 h. Total protein was harvested and subjected to Western blot
analysis with human anti-CTGF monoclonal antibody as described in materials and methods. Equal loading of protein samples was
ensured by prequantification of protein levels by the Bradford method initially, and verified following separation of the proteins by
Coomassie Brilliant Blue staining of the gels.
expression of iNOS was induced in MCs grown for 24 h
in medium containing 5 ng/ml TGF-b1 and 30 mM glu-
cose with 200 U/ml INFg and 10 mM BH4, or INFg alone
for 20 h in the presence or absence of 1400W. Condi-
tioned media were assayed for the presence of nitrites
using the Griess assay. Total RNA was harvested and
used for Northern blot analysis to test for iNOS, CTGF
and TSP-1 mRNA using gene-specific radioactively
labeled cDNA probes. iNOS protein was assayed by
Western blotting using polyclonal anti-iNOS antibodies.
iNOS mRNA and protein expression was detected after
20 h of stimulation with INFg and BH4 in human (Figure
3B) and rat MCs (data not shown). A decrease in CTGF
and TSP-1 mRNA levels was observed after the addition
of IFNg or IFNg plus BH4, corresponding to nitrite release
in the same set of experiments (Figure 3B). This decrease
was reversed by the addition of 1400W.
To further demonstrate that endogenously produced
NO in response to iNOS activation by INFg and BH4 can
lead to downregulation of CTGF and COL1A1, as well as
biglycan and COL1A2 (two additional ECM-associated
genes), quiescent human MCs grown for 24 h in medium
containing 30 mM glucose were treated with 200 U/ml
INFg and 10 mM BH4, or INFg alone for 20 h in the pres-
ence of 1400 W. Controls were not treated. Total RNA
was subjected to RT-PCR analysis using gene-specific
RT-PCR probes. Results showed a decrease in CTGF
(Figure 3C i), biglycan (Figure 3C ii), COL1A2 (Figure 3C
iii) and COL1A1 (Figure 3C iv) mRNA in samples treated
with INFg alone or INFg in combination with BH4.
1400W, a selective iNOS inhibitor, rescued the down-
regulatory effects of the combination of INFg and BH4,
indicating that the effects are NO-specific. Interestingly,
the effects of INFg alone were not rescued by 1400W
(Figure 3C).
Downregulation of CTGF by NO is not mediated by
changes in mRNA stability
To determine the effect of NO on CTGF mRNA stability,
Northern blot analysis of CTGF mRNA in human MCs
was performed after treatment with actinomycin D
(10 ng/ml) for up to 8 h in the presence or absence of
500 mM spermine NONOate. The rate of decay of CTGF
mRNA was of equivalent magnitude in cells grown in
spermine NO-treated media (Figure 4A,B), and the mes-
sage half-life was calculated to be less than 2 h in control
and spermine NO-treated media (Figure 4C). We con-
cluded that the decrease in the steady-state level of
CTGF mRNA induced by spermine NO treatment in MCs
is unlikely to be due to decreased mRNA stability,
although a small component of message destabilization
cannot be excluded.
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Figure 3 NO endogenously generated by the induction of iNOS with INF-g and BH4 downregulates the mRNA expression of different
genes involved in matrix accumulation in human MCs.
(A) Human mesangial cells grown and stimulated under the conditions stated above were left untreated or treated in the presence
of 200 U/ml INF-g or 200 U/ml INF-g plus 10 mM BH4, with or without 200 mM of 1400W, 100 mM L-NIL, or 250 mM L-NMMA. After
20 h, media were collected and assayed for nitrite content using the Griess assay. Data shown are mean"SD of three independent
experiments; ***p-0.001 compared to cells treated with 200 U/ml INF-g plus 10 mM BH4. (B) Quiescent human MCs grown in medium
containing 30 mM glucose and 5 ng/ml TGF-b1 for 24 h were left untreated or treated with 200 U/ml INF-g, 200 U/ml INF-g plus
10 mM BH4, 200 U/ml INF-g plus 200 mM 1400W or 200 U/ml INF-g plus 10 mM BH4 plus 200 mM 1400W for 20 h. Total RNA
extracted from unstimulated and stimulated cells was probed for CTGF, TSP-1, iNOS and 18S rRNA in a Northern blot analysis.
Whole-cell lysate from parallel experiments with similar conditions was used for the determination of iNOS protein. In this case, equal
amounts of total protein were subjected to SDS-PAGE and probed with an anti-rabbit iNOS polyclonal antibody as described in the
materials and methods section. For determination of the nitrite content, conditioned media from the same set of experiments were
subjected to the Griess assay at the time of termination of the experiments (20 h). Data shown are the mean of three independent
experiments (7 mM"SD; ***p-0.001) compared to medium from untreated cells (2 mM"SD; ***p-0.001). (C) cDNA synthesized from
2 mg of total RNA from the same set of experiments in (B) was subjected to real-time quantitative PCR using human RT-PCR
fluorescent probes for CTGF, COL1A1, COL1A2, biglycan (BGN), GAPDH and/or ribosomal RNA as described in the materials and
methods section.
NO inhibits putative CTGF promoter activity in MCs
To confirm that the decrease in the steady-state level of
CTGF mRNA induced by exogenous NO is due to a
decrease in gene transcription rate, promoter-reporter
gene assays using a putative CTGF promoter/SEAP
reporter construct were performed. Human MCs were
transiently transfected with a -805/q17-bp putative
human CTGF promoter construct (pCTGF-SEAP). Rela-
tive SEAP activity was measured 72 h after addition of
10, 100 or 250 mM NOC-18. Reporter analysis showed a
significant decrease (Figure 5A) in relative SEAP activity
(p-0.001) in NOC-18-treated cells compared to untreat-
ed controls. Stimulation of pCTGF-SEAP-transfected
cells with increasing doses of DetaNONOate and sper-
mine NONOate (Figure 5B) also showed a significant
decrease in reporter protein (SEAP) expression
(p-0.001). pSEAP-SV40-transfected human MCs stimu-
lated with different doses of NOC-18, and used as a pos-
itive control showed surprisingly significant upregulation
of relative SEAP activity (p-0.01) compared to untreated
control cells (Figure 5A), suggesting an effect on the
SV40 minimal promoter. These data demonstrate that
exogenously added NO can apparently act at the pro-
moter level to suppress TGF-b1- and glucose-induced
CTGF expression.
Discussion
The results detailed here expand our understanding of
the complex role of NO in regulating the expression of
genes in kidney MCs. The data presented confirm the
results of other investigators (Murphy et al., 1999; Keil
et al., 2002; Shi-Wen et al., 2006) and include a series of
unique observations that provide additional insight into
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Figure 4 CTGF mRNA stability is not affected by NO.
(A,B) Quiescent human MCs grown in serum-free medium con-
taining 30 mM glucose and 5 ng/ml TGF-b1 for 24 h were
exposed to actinomycin D alone (10 mg/ml) or to actinomycin D
(10 mg/ml) and spermine NO (500 mM). Total RNA from the stim-
ulated cells was subjected to Northern blot hybridization using
radiolabeled CTGF probes. (C) Graphic profile of CTGF mRNA
decay after treatment with actinomycin D for unstimulated cells
(j) or cells stimulated with 500 mM spermine NONOate (d).
Measurements at time 0 for actinomycin D treatment were
assigned a relative value of 100%. The average half-life of the
CTGF message was calculated to be approximately 2 h in both
treated and untreated samples.
Figure 5 NO inhibits putative CTGF promoter activity in a
SEAP reporter assay.
(A) Human MCs grown for 8 h in DMEM containing 10% FCS
were transfected with a putative CTGF promoter (-805 toq17)/
SEAP reporter plasmid (1.5 mg/well). After transfection, cells
were incubated in serum-free medium containing 30 mM glucose
and 5 ng/ml TGF-b1 for 24 h with or without 10, 100 and 250mM
NOC-18. Cells were co-transfected with SV40/SEAP positive
control plasmid (0.5 mg/well) and treated with 250 mM NOC-18
to show that NO does not exhibit any downregulatory effects on
a different and unrelated promoter. (B) Under similar conditions,
human MCs were transfected with CTGF promoter/SEAP report-
er or SEAP (-) plasmids (1.5 mg/well). Control cells were trans-
fected with a 1.5 mg/well SEAP reporter plasmid having no
promoter wSEAP (-)x. Transfected cells were left untreated or
treated with 50, 100 or 250 mM spermine NONOate or SNAP for
48 h, as indicated. Data represent the mean"SD of three inde-
pendent experiments with triplicate wells for each condition in
each setting (A,B). SEAP activity in relative light units was meas-
ured in conditioned media after 48 h using a SEAP fluorescent
assay kit as described in the materials and methods section. All
experiments were performed in 12-well plates. Values expressed
show significant differences in expression (**p-0.01 and
***p-0.001) relative to cells transfected with untreated or
untreated and co-transfected putative CTGF-promoter/SEAP
reporter plasmids.
the biological role of NO in moderating gene expression
in a fibrotic setting. Despite the limitations of RDA (such
as its low throughput), we were successful in identifying
several important ECM-associated genes downregulated
by GSNO treatment of glomerular MCs.
To confirm the RDA results, we used sublethal doses
of a series of additional NO donors and a human MC line
to verify the universality of changes in gene expression
elicited by GSNO treatment (Bannenberg et al., 1995) in
rat MCs. Human MCs were conditioned to maintain
amplified levels of matrix-associated genes and proteins
by treatment with TGF-b and high levels of glucose, thus
mimicking a fibrotic environment. Similar to previous
observations in GSNO-stimulated MCs (Rupprecht et al.,
2000), no cytotoxicity was observed either with GSNO or
other NO donors used in this study, except when NO
donor concentrations )250 mM were used in the inher-
ently stressful promoter transfection experiments.
Among the gene targets of NO identified in MC exper-
iments were type I collagen COL1A1 and COL1A2, bigly-
can, CTGF and TSP-1. Type I collagen is a major
component of the ECM, which is synthesized by fibro-
blasts and vascular smooth muscle cells and in the kid-
ney by glomerular MCs. Type I collagen is considered to
be centrally involved in progressive glomerular ECM
accumulation and is associated with chronic sclerotic
processes (Ortega-Velazquez et al., 2004). NO has pre-
viously been shown to inhibit the production of major
matrix components such as collagen, fibronectin, and
laminin in rat MCs (Trachtman et al., 1995; Craven et al.,
1997). The results presented here demonstrate that
genes linked to the structural component of ECM, such
as type I collagen, are targets of NO-mediated downre-
gulation. This may help to explain in part the role of NO
in tissue remodeling in chronic inflammatory kidney
diseases.
TSP-1 is an important ECM protein that has been
shown to be an activator of TGF-b in vivo (Crawford et
al., 1998; Daniel et al., 2004). TSP-1 is involved in diverse
biological activities that may be attributable to the mul-
tiple functional domains and different cell-surface recep-
tors associated with the protein. In addition, TSP-1 can
act as either a soluble or matrix-bound factor. In the stud-
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:49
Nitric oxide-regulated fibrosis in mesangial cells 503
Article in press - uncorrected proof
ies detailed here, treatment of MCs with high levels of
glucose and TGF-b resulted in increased basal expres-
sion of TSP-1, which was in turn downregulated by NO
stimulation. This observation is consistent with the
results of Wang et al. (2002). Our results further demon-
strate that different NO donors act in a time- and con-
centration-dependent manner to prevent increases in
steady-state TSP-1 mRNA. We also demonstrated a
decrease in TSP-1 protein levels in human MCs upon
exposure to high levels of glucose and TGF-b. This sug-
gests that NO may help to regulate the TSP-1 mRNA
levels that result from the ‘fibrotic’ environment mimicked
by treatment with high levels of glucose and TGF-b.
The observation that biglycan (BGN) is also a target of
exogenous or endogenous NO in human MCs is consis-
tent with studies by (Schaefer et al., 2003), who reported
that BGN is an NO-regulated gene in rat MCs both in
vitro and in vivo and that it is involved in the adhesion,
proliferation and survival of MCs. Biglycan is a member
of small, leucine-rich repeat glycoproteins/proteoglycans
(SLRPs), which are thought to play a role as organizers
of ECM (Hocking et al., 1998). Overexpression of BGN is
found in advanced stages of glomerulosclerosis (Davies,
1995). BGN is capable of inhibiting the proliferation of
MCs induced by PDGF-B, a major mitogenic growth fac-
tor frequently involved in glomerular disease (Blom et al.,
2001; Schaefer et al., 2003).
In our studies with CTGF, we observed a dose- and
time-dependent decrease in mRNA and protein expres-
sion with a series of NO donors. Downregulation ofCTGF
mRNA was also evident when endogenous NO release
was stimulated by the activation of iNOS with INFg and
BH4 in human MCs. These data are consistent with the
observations of Keil et al. (2002). CTGF, a secreted pro-
tein (Kireeva et al., 1997; Chen et al., 2002) is a member
of the CCN (CTGF, Cyr61, and Nov) family of proteins
that promote angiogenesis, cell migration, and cell adhe-
sion (Fan et al., 2000; Ivkovic et al., 2003). CTGF upre-
gulation is an important component in the pathogenesis
of mesangial matrix accumulation and progressive glo-
merulosclerosis, acting downstream of TGF-b (Riser et
al., 2000). CTGF is induced by TGF-b in fibroblasts and
acts synergistically with TGF-b to promote sustained
fibrosis (Chen et al., 2002). The induction of fibrosis by
high levels of glucose is thought to be mediated, at least
in part, by TGF-b. However, increased CTGF expression
has also been observed in cultured mesangial cells under
high glucose conditions (Gupta et al., 2000; Wahab
et al., 2001; Huang et al., 2003).
Our transient transfection studies using a CTGF-SEAP
reporter construct suggest that exogenously added NO
acts at the transcriptional level to downregulate glucose-
and TGF-b-mediated CTGF gene expression in both rat
and human MCs. These results were supported by
mRNA half-life experiments that showed that NO has a
limited effect on CTGF mRNA stability. CTGF expression
has been shown to be differentially regulated, depending
on the cell type and condition; however, our data are in
part consistent with observations by Chen et al. (2002)
confirming the induction of basal CTGF promoter activity
in MCs treated with TGF-b.
Our findings provide evidence that NO is capable of
downregulating COL1A2, COL1A2, BGN, CTGF and
TSP-1 gene expression in MCs. Using a series of NO
donors, we could show that for CTGF this regulation
occurred at the transcriptional level in a time- and con-
centration-dependent manner. Our data further demon-
strate that the reduction in mRNA levels by endogenously
generated NO was not caused by a direct cytokine effect,
since 1400W, a selective inhibitor of iNOS, counteracted
the NO effect. The exact mechanism and NO-responsive
cis-regulatory elements in the CTGF promoter are yet to
be identified. Previous work carried out by our group
suggests that the Egr-1 transcription factor is regulated
by NO (Rupprecht et al., 2000) and that Egr-1 may be
important for MC proliferation and matrix accumulation.
The results presented here, together with our previous
observation that NO has an antiproliferative effect on
MCs, suggest an important role for NO in regulating the
expression of profibrotic genes. Moreover, treatment
strategies employing optimal intervention with exoge-
nous NO donors might prove beneficial in certain disease
conditions with glomerular fibrosis.
Materials and methods
Reagents
S-Nitroso-L-glutathione (GSNO), spermine NONOate, 1400W
(dihydrochloride), L-NMMA (citrate), L-NIL and tetrahydro-L-
biopterin (dihydrochloride) (BH4Ø2HCl) were purchased from
Cayman Chemicals (Ann Arbor, MI, USA). SNAP, NOC-18, and
glutathione (GSH) were obtained from Calbiochem (Darmstadt,
Germany). Human and rat recombinant interferon g (INF-g), rat
recombinant interleukin-1b (IL-1b), rat recombinant tumor
necrosis factor a (TNF-a) and human transforming growth fac-
tor-1b (TGF-b1) were from Peprotech Inc. (Rocky Hill, NJ, USA).
D-(q)-Glucose solution was from Sigma-Aldrich (St. Louis, MO,
USA). Polyclonal anti-rabbit iNOS antibody was from Cayman
Chemicals. Human monoclonal anti-CTGF antibody (FG3019)
was from FibroGen Inc. (South San Francisco, CA, USA). Bovine
serum albumin (BSA) fraction V was from Roche (Mannheim,
Germany). Tri reagent was from Molecular Research Center Inc.
(Cincinnati, OH, USA); Griess Reagent System was from Pro-
mega (Madison, WI, USA); NuPAGE 4–12% Bis-Tris gels were
from Invitrogen Life Technologies (Carlsbad, CA, USA); poly-
vinylidine difluoride (PVDF) membranes from Bio-Rad (Munich,
Germany); Bright Star positively charged nylon membranes were
from Ambion (Austin, TX, USA); Great EscAPe fluorescent SEAP
Detection kit was from BD Biosciences (San Jose, CA, USA);
SuperFect Transfection Reagent, EndoFree Plasmid Max kit,
RNeasy mini kit and RNase-Free DNase were from Qiagen (Hil-
den, Germany); and Human TSP-1 EIA Kit was from PromoKine
(PromoCell GmbH, Heidelberg, Germany). Restriction enzymes
were from Roche Diagnostics (Penzberg, Germany).
Cell culture
Rat MCs were cultured as described by Pfeilschifter (1991). Pas-
sages 9–15 were used for experiments. All media and supple-
ments were purchased from Life Technologies (Basel,
Switzerland). Human MCs were propagated from a cell line as
described by Banas et al. (1999).
Representational difference analysis
RDA of cDNA was performed as described by Hubank and
Schatz (1994) with the Clontech PCR-Select cDNA Subtraction
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:49
504 J. Wani et al.
Article in press - uncorrected proof
Kit (Clontech, Palo Alto, CA, USA) according to the manufac-
turer’s protocol. For this purpose, poly-Aq RNA was extracted
from GSNO-treated and control MCs and reverse-transcribed
into cDNA. The cDNA containing the specific (differentially
expressed) transcripts was termed the tester, and the reference
cDNA, the driver. The tester and driver cDNAs were digested by
Rsa I, a four-base-cutting restriction enzyme that yields blunt
ends. The tester cDNA was then subdivided into two portions,
and each was ligated with a different cDNA adaptor. The two
adaptors had stretches of identical sequence to allow annealing
of PCR primers once the recessed ends had been filled in. Two
hybridizations were then performed. In the first, an excess of
driver was added to each tester sample. The samples were then
heat-denatured and allowed to anneal. The concentration of
high- and low-abundance sequences was equalized among the
single-strand molecules ligated to an adaptor because reannea-
ling is faster for the more abundant molecules due to the sec-
ond-order kinetics of hybridization. At the same time these
molecules were significantly enriched for differentially expressed
sequences. During the second hybridization, the two primary
hybridization samples and an excess of driver were mixed
together without denaturing. Now only the remaining equalized
and subtracted single-strand tester cDNAs could re-associate
and form hybrid double-strand tester molecules with different
ends, which correspond to the sequences of the different adap-
tors. The entire population of molecules was then subjected to
PCR to amplify the desired differentially expressed sequences.
Only the molecules that had two different adaptors could be
amplified exponentially. These were the equalized, differentially
expressed sequences. A secondary PCR amplification was per-
formed using nested primers to further reduce any background
PCR products and enrich for differentially expressed sequences.
For dot blot analysis to confirm differential expression of iden-
tified genes, equal amounts of cloned cDNAs were dotted twice
onto nylon membranes (Amersham LifeScience, Little Chalfont,
UK) as recommended by Clontech. The membranes were air-
dried and hybridized with wa32PxdCTP-labeled forward- and
reverse-subtracted cDNA probes of the GSNO-treated and
untreated mRNA populations. Blots were exposed to Kodak Bio-
max MS or MR films (Eastman Kodak Company, Rochester, NY,
USA) at -808C. Clones with confirmed differential expression in
the dot blot analysis were used for further tests in Northern blot
analysis.
For nitrite assay, conditioned media after stimulation with dif-
ferent NO donors or cytokines were collected over 24 h and
nitrite concentrations were measured using a colorimetric assay
with the Griess reagent. Absorbance at 550 nm was measured
in GENios Plus Microtiter plate reader (Tecan, Gro¨dig, Austria)
using XFluor4 software.
Northern blot analysis
Total RNA was isolated by Tri Reagent or an RNeasy kit accord-
ing to the manufacturer’s instructions. Total RNA (15 mg) was
subjected to electrophoresis on 1% formaldehyde agarose gels
and transferred to positively charged Bright Star nylon mem-
branes by downward alkaline transfer using 0.01 N NaOH. Blots
were hybridized in ExpressHyb solution (Clontech) with
2=106 cpm/ml wa32PxdCTP-labeled cDNA probes prepared using
a Prime-It RmT Random Primer Labeling Kit, Single-Use dCTP-
Labeling Reactions (Stratagene Europe). Probes for 18S rRNA,
CTGF and COL1A2 were obtained by restriction digestion of
RDA clones. The probe for TSP-1 (pTS-33) was purchased from
ATCC (Manassas, VA, USA), which yields a full-length cloned
TSP-1 cDNA fragment of 1.29 kb after restriction digestion with
EcoRI. Membranes were either exposed to a Kodak Bio Max X-
ray film or visualized after exposure to a Phosphorimager screen
and quantified by Image quantitation software (IQMac v 1.2) pro-
vided with the Phosphoimager Strom 840 (Molecular Dynamics,
Sunnyvale, CA, USA). X-Ray film blots were analyzed after scan-
ning by ImageJ version 1.32j image quantitation software (NIH).
Western blot analysis
Anti-iNOS rabbit polyclonal antibody from Cayman Chemicals
was used at a dilution of 1:1000. Anti-CTGF human monoclonal
anti-CTGF antibody was a gift from FibroGen, Inc. and used at
a 1:250 dilution. Equal loading of cell lysates was ensured by
prequantitation of protein levels by the Bradford method. Sam-
ples of 20 mg were subjected to electrophoresis through a
NuPAGE 4–12% Bis-Tris gel. After electrophoresis, proteins
were further visualized using a SuperSignal Chemiluminescent
kit (Pierce, Rockford, IL, USA). The gel was then transferred to
PVDF membranes. Membranes were blocked overnight in 2%
BSA, incubated with anti-iNOS or anti-CTGF antibody for 1 h
and with secondary horseradish peroxidase IgG antibody for
45 min.
ELISA
Quantitation of thrombospondin-1 (TSP-1) protein secreted into
the culture medium was performed using a competitive
PromoKine Human TSP-1 enzyme immunoassay (EIA), which
measures the natural and recombinant forms of TSP-1. Human
mesangial cells were plated in 24-well culture plates at 70 000
cells/well in growth medium and incubated for 1–3 days until
subconfluency. Cells were then serum-starved for 24 h in Dul-
becco’s modified Eagle medium containing 30 mM D-glucose
and 5 ng/ml TGF-b1. Thereafter, cells were treated with 100, 250
or 250 mM spermine NONOate, SNAP or NOC-18 for 12 and
24 h in the same medium. The culture medium was then col-
lected, clarified by centrifugation and used immediately for
assay or stored at -708C until assayed. Samples were processed
according to the manufacturer’s instructions and the readings
were performed at 490 nm in a GENios Plus Microtiter plate
reader (Tecan) using XFluor4 software, until the OD of the growth
medium reached 1.6. At this time point, 20 ml of stop solution
was added to each well and the plate was read again. A stan-
dard curve with recombinant TSP-1 protein standard was run at
each setting. Reverse transcription was performed for 60 min at
428C in a volume of 20 ml using a modified Moloney-murine
leukemia virus (MMLV) reverse transcriptase (Superscript and
respective buffer; Life Technologies, Karlsruhe, Germany). This
was performed in the presence of 1 mM dNTPs (Amersham
Pharmacia, Freiburg, Germany), 40 U of RNase inhibitor (RNasin;
Promega, Mannheim, Germany), 2 ml of dithiothreitol (DTT; Life
Technologies), 2 ml of random hexamers (Roche), and 7 ml of
the above RNA solution.
Real-time quantitative RT-PCR
Real-time RT-PCR was performed on a TaqMan ABI 7700
Sequence Detection System (Applied Biosystems, Weiterstadt,
Germany) using heat-activated Taq DNA polymerase (Amplitaq
Gold, Applied Biosystems). After an initial hold of 2 min at 508C
and 10 min at 958C, the samples were cycled 40 times at 958C
for 15 s and 608C for 60 s. The cDNA content of each sample
was compared with another sample according to the DCt tech-
nique. This procedure uses the formula A0/B0s(1qE)(CtB-CtA)
where A0 is the initial copy number of sample A, B0 is the initial
copy number of sample B, E is the amplification efficiency, CtA
is the threshold cycle for sample A, and CtB is the threshold
cycle for sample B. The amplification efficiency was defined as
1, as all analyses were performed during the same runs, includ-
ing control dilution series. Similar amplification efficiencies for
targets and housekeeping genes were demonstrated by analyz-
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ing serial cDNA dilutions showing an absolute value of the slope
of log input cDNA amount versus DCT (Ct housekeeping gene-
Ct target) of -0.1.
Commercially available human TaqMan Gene Expression
assays with the following GenBank accession numbers and/or
probe sequences were purchased from Applied Biosystems to
perform RT-PCR: collagen type I a1 (COL1A1; NM_000088), 59-
ACG AAG ACA TCC CAC CAA TCA CCT-39; collagen type I a2
(COL1A2; NM_000089), 59-TGG TCC AGC TGG CCC TCC TGG
CAA-39; biglycan (BGN; NM_001711), 59-CCC TCT CCA GGT
CCA TCC GCC AT-39; and GAPDH (M33197); connective tissue
growth factor (CTGF; NM_001901), sense primer 59-ACG AGC
CCA AGG ACC AAA C-39, antisense primer 59-TCT GGG CCA
AAC GTG TCT TC-39, fluorescently labeled probe 59-TCG GTA
AGC CGC GAG G-39; inducible nitric oxide synthase (NOS2;
NM_000625), sense primer 59-ACA ACA GTA ACC TAC CAA
CTG ACG G-39, antisense primer 59-CCT CCC AAT GCA GCG
TG-39, fluorescently labeled probe 59-TGA GCT CAT CTT CGC
CAC CAA GCA-39. All these assay reagents do not amplify
genomic DNA. This was verified using genomic human DNA
samples. Controls consisting of ddH2O were negative in all runs.
Message stability assay
Quiescent human MCs grown in serum-free medium containing
30 mM glucose and 5 ng/ml TGF-b1 for 24 h were exposed to
actinomycin D alone (10 mg/ml) or to actinomycin D (10 mg/ml)
and spermine NO (500 mM). Total RNA from stimulated cells
(between 0 and 6 h) was subjected to Northern blot hybridization
using radiolabeled probes for CTGF and 18S rRNA to measure
the rate of decay of CTGF mRNA. Measurement of the CTGF/
18S rRNA ratio at times0 for actinomycin D treatment in cells
cultured in 500 mM spermine NONOate was assigned a relative
value of 100%. The half-life was calculated according to the
equation: t1/2sln2/l, where ln is the natural logarithm and l is
the rate of decay of the message.
Transient transfections and SEAP assay
Rat or human MCs grown for 8 h to 50% confluence in DMEM
containing 10% FCS were transfected with a putative CTGF pro-
moter (-805 to q17)/SEAP reporter plasmid pCTGF-SEAP
(FibroGen, Inc.). Transfections were carried out using Superfect
transfection reagent (Qiagen) at a DNA/Superfect ratio of 1:2,
i.e., 1.5 mg of plasmid DNA and 3 ml of Superfect per well in a
12-well plate. After transfection, cells were incubated in serum-
free medium containing 30 mM glucose and 5 ng/ml TGF-b1 for
up to 48 h with or without 10, 100 and 250 mM NOC-18, sper-
mine NONOate or SNAP. In co-transfection experiments, cells
were transfected with 1.5 mg/well SEAP reporter plasmid with
no promoter wpSEAP (-)x as a negative control. Cells were trans-
fected with pSV40/SEAP positive control plasmid (0.5 mg/well)
as a positive control. In the positive control experiments, cells
were additionally treated with 50–250 mM NOC-18 to show that
the control promoter activity was at least not downregulated by
NO. SEAP protein was measured without any dilution of the con-
ditioned media using a Great EScAPe SEAP Fluorescent detec-
tion kit (BD Biosciences) according to the manufacturer’s
instructions. The assay was performed in BD Falcon Microtest
96-well Optilux assay plates with black walls, a clear bottom and
a tissue culture surface (BD Biosciences). Plates were read in a
GENios Plus Microtiter plate reader (Tecan) using XFluor4 soft-
ware at excitation and emission wavelengths of 360 and 449 nm,
respectively. Suitable standards were used to stay within the
linear range of the assay as described in the manufacturer’s pro-
tocol. Relative SEAP activity is determined as fluorescent units.
Experiments were performed multiple times and values are rep-
resented as mean"SD.
Statistical analysis
All results are expressed as mean"SD unless otherwise stated.
Student’s unpaired t-test was used for statistical analyses. Val-
ues of p-0.05 were considered statistically significant.
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